June 20-22, 2018
Boston, MA
Only 34 Passes Remaining – Secure Yours Now

2018 Speakers

Expand/Collapse

David Donabedian
CEO
Axial Biotherapeutics

Ravi Starzl
CEO
Bioplx

Adrien Nivoliez
CEO
Biose

Adham Aljahami
Co-founder, CEO
Blue Turtle Bio Technologies, Inc

Day Two

Friday June 22, 2018

15.50 | Known Unknowns - An Outsiders Perspective On The Cost Of Being at The Forefront Of Biotech’s New Chapter

Jeffrey Heiser
Director Microbiology
Boston Analytical

Day One

Thursday June 21, 2018

16.30 | Application of Multivalent Vaccine Manufacturing Testing Schemes in cGMP Characterization of Microbiome Defined Drug Products

Ben Bradley
Technology Innovation Lead
CHAIN Biotechnology Ltd

Ian Parsons
Director Analytical Laboratories
Charles River Laboratories

Rana Samadfam
Scientific Director
Charles River Laboratories

Stanley Hazen
Head of Preventative Cardiology and Rehabilitation
Cleveland Clinic

Manoj Dadlani
CEO
CosmosID

Dan Knights
CEO
CoreBiome

Day Two

Friday June 22, 2018

09.00 | Powering Microbiome Discovery with Big Data

Cathryn Nagler
Bunning Food Allergy Professor, University of Chicago
President, ClostraBio

Day One

Thursday June 21, 2018

09.30 | The Gut Microbiome, Immunity and Allergic Disease

Bjorn Nielsen
Chief Scientific Officer
Clinical-Microbiomics

Day One

Thursday June 21, 2018

10.00 | What Microbiome Systems Biology Can Tell About Mechanism

Julie Cope
Director Scientific Operations
Diversigen

Day One

Thursday June 21, 2018

09.00 | Microbiome Tools & Trends for the Pharmaceutical Industry

Evgueni Doukhanine
Scientist, Microbiome
DNA Genotek

Xavier Duportet
CEO
Eligo Biosciences

Christophe Bonny
Chief Scientific Officer
Enterome Bioscience

Rodolphe Clerval
Chief Business Officer
Enterome Bioscience

Workshop B

Wednesday, June 20

11.00am | Insights into Study Design & Analysis for Commercial Success in Microbiome Product Development

Paul Carlson
Principal Investigator
FDA

Day One

Thursday June 21, 2018

17.30 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

16.10 | Regulatory Considerations for Live Biotherapeutic Products & Bacteriophage Therapy

Mark Smith
CEO
Finch Therapeutics Group

Kirk Taylor
Chief Medical Officer
Finch Therapeutics Group

Bharat Dixit
VP Bioprocess Development & Manufacturing
Finch Therapeutics Group

Craig Thomson
Partner
HGF

Craig has considerable experience in providing pragmatic, commercially focused advice to a wide-range of clients and in relation to biotechnological, pharmaceutical, chemical and MedTech inventions. As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, preparing for or carrying out funding/acquisition due diligence, and advising on aggressive/defensive strategies in relation to third-party IP.

Phil Strandwitz
Co-Founder and CEO
Holobiome, Inc

Anuk Das
Head, Scientific Innovation
Janssen Human Microbiome Institute

Georges Rawaldi
CEO
LNC Therapeutics

Tuval Ben-Yehezkel
CEO
Loop Genomics

Jason Ryan
Senior Scientist
Luina Bio

Alessio Fasano
Allan Walker Chair in Paediatric Gastroenterology & Nutrition
Massachusetts General Hospital

Workshop B

Wednesday, June 20

11.00am | Insights into Study Design & Analysis for Commercial Success in Microbiome Product Development

Michael Romanos
CEO
Microbiotica

Trevor Lawley
Chief Scientific Officer
Microbiotica

Day Two

Friday June 22, 2018

10.00 | Culturing the Unculturable to Enable Precision Metagenomics

Henry Haiser
Investigator III
Novartis Institutes for BioMedical Research (NIBR)

Michiel Wels
Group Leader Microbiomics
NIZO

Magali Cordaillat-Simmons
Scientific and Regulatory Affairs Director
PRI

Day One

Thursday June 21, 2018

17.30 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

17.00 | Regulatory Challenges for Registering Live Biotherapeutic Products in Europe

Massimo Marzorati
Chief Business Officer
ProDigest

Dean Scholl
Scientist
Pylum Biosciences

Eva Berkes
Chief Scientific Officer
Quorum Innovations

Day Two

Friday June 22, 2018

15.10 | What is the Role of Biofilms in Human Microbiome Discovery?

Ryan Wilson
Head of Live-Bio Programmes
Quay Pharma

Ryan has led Quay’s clinical development service business for oral LBT drug products.  He has championed multiple projects working on both single strain and consortia products for both Phase I and Phase II clinical studies; involving both IMPD and IND submissions.  Ryan has over 20 years’ experience spanning various technical, CMC outsourcing and programme management roles in the pharma and biotech sectors.

Ken Blount
Chief Scientific Officer
Rebiotix

Day Two

Friday June 22, 2018

09.30 | Using the “Microbiome Health Index” to Identify Indicators for Microbiome Restoration

Edward Burd
Head of Regulatory Affairs
Rebiotix

Day One

Thursday June 21, 2018

17.30 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

Matt McClure
Chief Medical Officer
Second Genome

Jennifer Russo Wortman
Senior Director, Bioinformatics
Seres Therapeutics

Jennifer Russo Wortman is the Senior Director of Bioinformatics at Seres Therapeutics. Her areas of expertise include genome assembly and annotation, comparative genome and metagenome analysis, bioinformatics tool development and large-scale data management. Prior to joining Seres Therapeutics, Jennifer was the Director of Microbial Informatics at the Broad Institute, responsible for the computational infrastructure and analytical strategies supporting the Genome Center for Infectious Diseases (GCID). That followed three years as Associate Director of Bioinformatics at the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine, where she was the co-Principal Investigator of the Human Microbiome Project's Data Analysis and Coordination Center (HMP DACC). She has over 70 peer-reviewed publications and has made significant contributions to the published genome analyses of the fruit fly, human, mouse, and mosquito as well as diverse pathogenic fungi, parasites, and bacteria.

Day One

Thursday June 21, 2018

08.30 | Unraveling Microbiome Signatures for Drug Design: Clinical Immune Modulation by Microbiome Therapeutics

Jim Weston
SVP, Regulatory Affairs
Seres Therapeutics

Jim Weston is a veteran regulatory affairs and quality executive with a demonstrated ability to spearhead the drug development process by crafting effective regulatory and clinical strategies world-wide, including the US, Canada, Europe (centralized and member states), Australia and Japan. His knowledge of domestic and international regulatory requirements and his close interactions with regulatory authorities has resulted in successful and timely implementation of clinical trial programs and integrated regulatory submissions, including investigational and marketing applications that resulted in the approval of more than 11 drugs/biologics worldwide. Jim is passionate about drug development and has extensive experience in structuring and coaching high-performance drug development teams. He is able to act decisively to meet key regulatory objectives and to instill creative energy and motivation to all involved in the drug development process to achieve success.

Day One

Thursday June 21, 2018

17.30 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

Lata Jayaramen
Head, Tumor Immunotherapy
Seres Therapeutics

Workshop C

Wednesday, June 20

15.00pm | The Role of the Microbiome to Improve Immunotherapy Outcomes

Ward Peterson
CEO
Symberix

Isil Tuzun Weber
Process Engineer
SynCo Bio Partners

Dick Schwartz
SVP Process Development & Manufacturing
Synlogic Therapeutics

Marja Puurenen
Associate Medial Director
Synlogic Therapeutics

Caroline Kurtz
Head of Translational Sciences & Product Development
Synlogic Therapeutics

Christian Furlan Freguia
Director of Research
Synthetic Biologics

Jessica Schneider
Associate Scientific Director
Takeda

Day Two

Friday June 22, 2018

08.30 | Prioritizing Indications for Microbiome Therapeutics: Where do we go after C.difficile and UC?

Natalia Palacios
Assistant Professor
UMass Lowell

Workshop A

Wednesday, June 20

08.30am | Understanding Parkinson’s Disease Through the Gut Microbiome: Possibilities for New Interventions

Rita Colwell
Distinguished University Professor
University of Maryland

Workshop B

Wednesday, June 20

11.00am | Insights into Study Design & Analysis for Commercial Success in Microbiome Product Development

Bruce Roberts
Chief Scientific Officer
Vedanta Biosciences

David Beno
Chief Scientific Officer
Xeno Biosciences

Day Two

Friday June 22, 2018

15.30 | Pharmacological Mimicry of the Gastric Bypass Microbiome to Treat Obesity